XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue- Gilead Science Inc (Details) - USD ($)
$ in Thousands
 3 Months Ended 7 Months Ended
Oct. 14, 2022
Mar. 31, 2024
Mar. 31, 2023
Jul. 31, 2022
Dec. 31, 2023
Sep. 30, 2023
Collaboration And Other Agreements [Line Items]            
Revenues   $ 9,104 $ 24,496      
Deferred revenue, current   22,837     $ 21,651  
Deferred revenue, net of current portion   56,182     59,243  
Gilead | 2022 Gilead Collaboration And License Agreement            
Collaboration And Other Agreements [Line Items]            
Non-refundable upfront payment       $ 60,000    
Revenues   300 $ 400      
Deferred revenue   58,000     58,300  
Deferred revenue, current   1,800     2,200  
Deferred revenue, net of current portion   56,200     56,100  
Potential target nomination, option fees and milestone payments $ 1,700,000          
Gilead | Gilead First Research Program            
Collaboration And Other Agreements [Line Items]            
Revenues   700        
Deferred revenue   14,200     14,900  
Deferred revenue, current         11,800  
Deferred revenue, net of current portion         $ 3,100  
Revenue, remaining performance obligation, amount   $ 15,700       $ 15,700
Potential option fees           $ 10,000